Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 29, 2012. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 742,750 Ordinary Shares of 25 pence each.
- Purchase Date: November 29, 2012.
- Price Range: Highest price paid was 1,355.5 pence per share; lowest price paid was 1,339.0 pence per share.
- Treasury Holdings: 490,140,427 shares held in Treasury (9.08% of total issued share capital).
- Voting Rights Impact: Including unsettled purchases, Treasury shares represent 9.98% of total voting rights.
- Shares in Issue: 4,910,030,637 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding share capital through the cancellation of 742,750 repurchased shares. Consequently, the percentage of total voting rights held in Treasury increased to 9.98% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. It is a routine disclosure of a share repurchase activity compliant with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (4,910,030,637) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the current Treasury share count (490,140,427) and its impact on voting rights (9.98%).
- Note that the repurchased shares are cancelled, permanently reducing the share count.
- Recognize that this document does not contain financial performance data; refer to the latest Form 20-F for revenue and earnings metrics.